Charlie Dawson
Authored Items
TOP - March 2022 Vol 15, No 2
Vaccination with the mRNA-1273 vaccine (Moderna) appears safe in patients with solid tumors receiving immunotherapy, chemotherapy, or chemoimmunotherapy. Read More ›
TOP - January 2022 Vol 15, No 1 – Online Only
The ongoing COVID-19 pandemic has brought to the forefront the importance of advance care planning. Read More ›
TOP - January 2022 Vol 15, No 1 – Online Only
Oncologic drug pricing is being transformed with greater value in mind. Read More ›
TOP - November 2021 Vol 14, No 7
Preliminary results from the first prospective study of a genomic classifier for African-American men suggest that both disparities in access to care and biological factors may be responsible for the increased incidence and mortality in this patient population. Read More ›
TOP - November 2021 Vol 14, No 7
The addition of 177Lu-PSMA-
617, a radionuclide therapy that targets prostate-specific membrane antigen (PSMA), to standard-of-care treatment resulted in a 38% reduction in the risk for death versus standard of care alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase 3 VISION clinical trial, which were presented during a plenary session at the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting. Read More ›
TOP - October 2021 Vol 14, No 6 | Biosimilars
Adoption of biosimilars continues to rise in the United States, but oncologists’ knowledge regarding these agents has not kept pace, according to data presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium. Read More ›
TOP - October 2021 Vol 14, No 6 | Biosimilars
Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to life-saving therapies. Read More ›
TOP - October 2021 Vol 14, No 6 | Biosimilars
Rapid adoption of FDA-approved biosimilars is feasible, measurable, and scalable—and pharmacists should lead the charge, according to data presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium. Read More ›
TOP - September 2021 Vol 14, No 5
Over the past 2 decades, the number of cancer deaths per 100,000 blacks has declined approximately 30% in the United States, but black people are still disproportionately dying of cancer. Read More ›
TOP - September 2021 Vol 14, No 5
The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial. Read More ›
TOP - July 2021 Vol 14, No 4
The process of clinical trials underwent a dramatic transformation amid the COVID-19 pandemic, according to Heidi D. Finnes, PharmD, BCOP, FHOPA, RPh, Senior Manager, Pharmacy Cancer Research, Mayo Clinic, Rochester, MN. Read More ›
TOP - July 2021 Vol 14, No 4
For more than 40 years, healthcare professionals, public health advocates, and healthcare strategists have been discussing health inequities that consistently and disproportionately affect groups of color in the United States. Read More ›
TOP - July 2021 Vol 14, No 4
The COVID-19 pandemic may have temporarily overshadowed the opioid crisis in the United States, but deaths related to opioid overdose deaths have risen to an all-time high in the past year. Read More ›
TOP - July 2021 Vol 14, No 4
Thrombosis in patients with cancer may be a relatively common complication, but the treatment of venous thromboembolism (VTE) in this patient population is anything but simple. Read More ›
TOP - July 2021 Vol 14, No 4
Lung cancer remains the leading cause of cancer death worldwide, but the treatment landscape is rapidly evolving. Read More ›
TOP - July 2021 Vol 14, No 4
The recent approval of several new HER2-targeted therapies has led to significant advances in the treatment of patients with HER2-positive metastatic breast cancer. Read More ›
TOP - July 2021 Vol 14, No 4
Although standard chemotherapy is often effective in the first-line treatment of locally invasive urothelial carcinoma, until recently, there have been few second- or third-line treatment options for patients with advanced or metastatic disease. Read More ›
TOP - July 2021 Vol 14, No 4
According to the American Cancer Society, nearly 35,000 new cases of multiple myeloma will be diagnosed in the United States in 2021, and approximately 12,410 deaths will be attributed to the disease.1 However, with the introduction of several novel therapies, the outcomes for patients with newly diagnosed multiple myeloma have improved significantly over the past decade. Read More ›
TOP - March 2021 Vol 14, No 2
Results of a phase 1 clinical trial showed that approximately 66% of patients with chronic-phase chronic myeloid leukemia (CML) had a major cytogenetic response (MCyR) to the novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI) vodobatinib, regardless of whether they previously received ponatinib therapy. Read More ›
TOP - March 2021 Vol 14, No 2
Enrollment in clinical trials is vital for the advancement of knowledge and improvement of patient outcomes, but few adults participate in cancer clinical trials. The numbers are even lower among minority adolescent and young adults (AYAs). Read More ›
TOP - March 2021 Vol 14, No 2
The use of a screening method followed by a financial toxicity intervention that involves navigators, pharmacists, and financial counselors demonstrated significantly improved quality of life for patients with hematologic malignancies, said lead investigator Thomas Greg Knight, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, at ASH 2020. Read More ›
TOP - March 2021 Vol 14, No 2
A new step-up dosing schedule with glofitamab, an investigational T-cell engaging bispecific antibody, has demonstrated strong clinical activity, with high complete response rates in patients with hard-to-treat relapsed or refractory non-Hodgkin lymphoma (NHL), according to data presented at the ASH 2020 annual meeting. Read More ›
TOP - January 2021 Vol 14, No 1
The COVID-19 pandemic has had a profound impact on cancer care delivery in the United States—for the worse, but also for the better. Although access to high-quality care has certainly been compromised, the pandemic has also driven innovation, according to information presented at the 2020 ASCO Quality Care Symposium by experts who discussed recent healthcare transformations from the perspectives of community oncology and a larger healthcare system. Read More ›
TOP - January 2021 Vol 14, No 1
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in applying the use of targeted therapies in the treatment of patients with cholangiocarcinoma (CCA). Read More ›
TOP - January 2021 Vol 14, No 1
Protecting patients with cancer from financial hardship could save more than money. According to data presented at the 2020 ASCO Quality Care Symposium, mitigating the financial burden of cancer treatment on patients could save lives as well. Read More ›
TOP - January 2021 Vol 14, No 1
Cancer does not discriminate based on social status, race, income, or education, but that does not mean that it is an equal-opportunity killer. Read More ›
TOP - January 2021 Vol 14, No 1
Myriad new treatment options have extended the survival and improved the quality of life for patients with cancer, but these options are also increasing the complexity of care. Read More ›
TOP - September 2020 Vol 13, No 5
An analysis of the Value Framework of the American Society of Clinical Oncology (ASCO) shows that the Net Health Benefit score of cancer drugs continues to evolve over time after their FDA approval, based on data presented at the ASCO 2020 virtual annual meeting. This analysis showed a substantial change in more than 25% of cancer drugs in their Net Health Benefit 3 years after their initial approval. Read More ›
TOP - September 2020 Vol 13, No 5
As the complexity of cancer care continues to evolve, adhering to evidence-based treatment guidelines is a growing challenge for oncologists. The use of clinical decision support tools within the electronic health record (EHR) system can boost provider compliance and drive quality improvement, according to data presented at the ASCO 2020 virtual annual meeting. Read More ›
TOP - September 2020 Vol 13, No 5
A novel intratumoral chemotherapy agent delivered by direct injection permits the dispersion of cytotoxic drugs into cancer cells to eradicate tumors. Read More ›
TOP - September 2020 Vol 13, No 5
There is a new standard of care in the first-line treatment setting for the subset of patients with advanced colorectal cancer (CRC) that is associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), according to data presented at the ASCO 2020 virtual annual meeting. Read More ›
TOP - September 2020 Vol 13, No 5
Targeted therapy with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence), which is currently approved for the treatment of patients with non-Hodgkin lymphoma, has demonstrated durable remissions in treatment-naïve patients with chronic lymphocytic leukemia (CLL), according to the long-term data from the phase 2 CLL-001 study, which were presented at the ASCO 2020 virtual annual meeting. Read More ›
TOP - September 2020 Vol 13, No 5
The combination of carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone (KRd) as induction therapy does not improve outcomes in patients newly diagnosed with multiple myeloma compared with the current standard of care with bortezomib (Velcade), lenalidomide, and dexamethasone (VRd). Read More ›
TOP - September 2020 Vol 13, No 5
Cellular therapy is becoming an attractive option for heavily pretreated patients with relapsed or refractory multiple myeloma. According to data presented at the ASCO 2020 virtual annual meeting, 2 chimeric antigen receptor (CAR) T-cell drugs have generated impressive rates of response that are sustainable. Read More ›
TOP - September 2020 Vol 13, No 5
New research highlights the importance of germline analysis in the identification of germline alterations for cancer treatment. According to a large analysis presented at the ASCO 2020 virtual annual meeting, nearly 9% of patients with advanced cancer harbor a targetable germline variant. Read More ›
TOP - September 2020 Vol 13, No 5
Cemiplimab-rwlc (Libtayo), a new PD-1 inhibitor, has transformed the treatment of advanced cutaneous squamous-cell carcinoma (CSCC), significantly extending survival for patients. Read More ›